### **Report From Agency**

# STATE OF WISCONSIN MEDICAL EXAMINING BOARD

IN THE MATTER OF RULEMAKING	:		
PROCEEDINGS BEFORE THE	:	<b>REPORT TO THE LEGISLATURE</b>	
MEDICAL EXAMINING BOARD	:	CR 22-067	

## I. THE PROPOSED RULE:

The proposed rule, including the analysis and text, is attached.

#### II. REFERENCE TO APPLICABLE FORMS: N/A

**III. FISCAL ESTIMATE AND EIA:** The Fiscal Estimate and EIA is attached.

# IV. DETAILED STATEMENT EXPLAINING THE BASIS AND PURPOSE OF THE PROPOSED RULE, INCLUDING HOW THE PROPOSED RULE ADVANCES RELEVANT STATUTORY GOALS OR PURPOSES:

The objective of this rule was to update ch. Med 13 to extend the requirement that 2 of the 30 required continuing medical education (CME) hours per biennium shall be in a course or program related to opioid prescribing. This requirement was also modified to include courses or programs concerning controlled substances in general, not just opioid substances. Additionally, the Board removed the requirement that educational programs related to opioid prescribing or controlled substances be pre-approved by repealing section Med 13.03 (3).

# V. SUMMARY OF PUBLIC COMMENTS AND THE BOARD'S RESPONSES, EXPLANATION OF MODIFICATIONS TO PROPOSED RULES PROMPTED BY PUBLIC COMMENTS:

The Medical Examining Board held a public hearing on December 21, 2022. The following people either testified at the hearing, or submitted written comments:

• Mark Grapentine, JD, Chief Policy and Advocacy Officer, Wisconsin Medical Society

The Medical Examining Board summarizes the comments received either by hearing testimony or by written submission as follows:

• The Wisconsin Medical Society testified in support of the proposed rule The Medical Examining Board explains modifications to its rule-making proposal prompted by public comments as follows:

• No further changes were made to the proposed rule

VI. RESPONSE TO LEGISLATIVE COUNCIL STAFF RECOMMENDATIONS: All recommendations suggested in the Clearinghouse Report have been accepted in whole.

# VII. REPORT FROM THE SBRRB AND FINAL REGULATORY FLEXIBILITY ANALYSIS: N/A